We hypothesized that the number of circulating tumor cells (CTCs) and molecular markers on CTCs could be a prognostic factor or predictive factor to patients with head neck cancer.
1. Histologically or cytopathologically proven head and neck squamous cell carcinoma (HNSCC) 2. Disease status: locally advanced or recurrent/metastasized at initial presentation 3. Age \>=20 years old 4. Could understand and signed the informed consents of this study 5. Enrolled patients were classified into three distinct subgroups: 1. Patients underwent curative surgery followed by adjuvant chemoradiotherapy (CRT) because of some pathologic features such as positive margin, pathologic N2, and extracapsular spread (ECS) of involved lymph nodes indicating early relapse according to recommendation from National Comprehensive Cancer Network(NCCN) guidelines; 2. Patients with advanced disease directly underwent definitive concurrent chemoradiotherapy(CCRT); 3. Patients were to have palliative chemotherapy for existence of distant metastasis or poor general condition for definitive CCRT. 6. Blood samples were collected within 7 days before the first dose of chemotherapy.
Study Type
OBSERVATIONAL
Enrollment
53
Chang Gung Memorial Hospital
Taoyuan District, Taiwan
Progression-free survival
Measure response or progression events via all available imaging studies, including Chest-Xray, CT scans, or MRI, PET study. The relationship between CTCs number and time from CTCs checkpoint to disease progression will be analyzed.
Time frame: one year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.